Chief Scientific Officer

Stephen Demarest has over 20 years of antibody and multi-specific protein development experience in both biotech and pharma. He contributed to more than 10 molecules that reached IND-enabling studies and managed departments that moved many more. Stephen’s career began as a scientist at Syngenta and Diversa before moving into the role of Associate Director of Protein Sciences at Biogen Idec. Before coming to Tentarix, Stephen was the head of Lilly’s Protein Engineering and Computational Biotherapeutics Departments and a liaison to Immunology and Oncology. Stephen is a co-developer of Lilly’s OrthoMab bispecific technology with partners at UNC Chapel Hill and used the technology to bring many bispecific monoclonal antibodies into development, including with external partners. The technology has also been licensed by AbCellera. Stephen has >45 publications and is an inventor on >20 granted patents and applications.

Stephen holds a B.S. in Chemistry from Texas A&M University and a Ph.D. in Chemistry from SUNY Stony Brook. His postdoctoral studies were at The Scripps Research Institute.